Rob Christiaan van Wijk

Has grant

Assistant professor / Principal investigator "Translational Immuno-Pharmacology"

Leiden University

Netherlands

Research Interests

Explore related searches

Professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Rob Christiaan van Wijk is an Assistant Professor and Principal Investigator in Translational Immuno-Pharmacology at Leiden University, Netherlands. His research areas include the treatment of tuberculosis, pharmacometrics, and the efficacy of BCG vaccination in relation to COVID-19. He has authored several recent articles focusing on drug efficacy, in vitro assays, and optimization in drug discovery.

Recent Grants

Grant: Open

Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium

Open Date: 2024-03-26

Close Date: 2029-02-28

Articles (10)

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Kelly E. Dooley

Johns Hopkins University School of Medicine

UNITED STATES

View details

Ulrika S. H. Simonsson

Uppsala University

SWEDEN

View details

Cyril Gaudin

Institut Pasteur de Lille

FRANCE

View details

Bree Aldridge

Professor

Tufts University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Rob Christiaan van Wijk

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Predicting tuberculosis drug efficacy in preclinical and clinical models from in vitro data.

Selection and prioritization of candidate combination regimens for the treatment of tuberculosis.

Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19

Implementing best practices on data generation and reporting of <i>Mycobacterium tuberculosis</i> <i>in vitro</i> assays within the ERA4TB consortium

Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial

Finding the right hazard function for time‐to‐event modeling: A tutorial and Shiny application

Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial

Anti‐tuberculosis effect of isoniazid scales accurately from zebrafish to humans

Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations

Segmentation-driven Optimization for Iterative Reconstruction in Optical Projection Tomography: An Exploration

Collaborators (4)

Kelly E. Dooley

Ulrika S. H. Simonsson

Cyril Gaudin

Bree Aldridge

Make your next move.

Rob Christiaan van Wijk

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Predicting tuberculosis drug efficacy in preclinical and clinical models from in vitro data.

Selection and prioritization of candidate combination regimens for the treatment of tuberculosis.

Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19

Implementing best practices on data generation and reporting of &lt;i&gt;Mycobacterium tuberculosis&lt;/i&gt; &lt;i&gt;in vitro&lt;/i&gt; assays within the ERA4TB consortium

Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial

Finding the right hazard function for time‐to‐event modeling: A tutorial and Shiny application

Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial

Anti‐tuberculosis effect of isoniazid scales accurately from zebrafish to humans

Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations

Segmentation-driven Optimization for Iterative Reconstruction in Optical Projection Tomography: An Exploration

Collaborators (4)

Kelly E. Dooley

Ulrika S. H. Simonsson

Cyril Gaudin

Bree Aldridge

Make your next move.

Implementing best practices on data generation and reporting of <i>Mycobacterium tuberculosis</i> <i>in vitro</i> assays within the ERA4TB consortium